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Background
Sepsis is defined as life-threatening organ dysfunction caused 
by a dysregulated host response to infection, and septic shock is 
defined as a subset of sepsis in which underlying circulatory, 
cellular, and metabolic abnormalities are profound enough to 
substantially increase mortality.1
Although the true incidence remains uncertain, conserva-
tive estimates indicate that sepsis is a leading cause of mortal-
ity and critical illness worldwide contributing to up to 
5.3 million deaths worldwide per annum.2 A study conducted 
in a general hospital in southern Brazil noted that 30% of 
admitted patients had sepsis and mortality was 66.5%.3 Silva 
et al4 reported the results of a prospective multicenter inten-
sive care unit (ICU) screening study conducted in Brazil more 
than 9 months in 2001, in which they found an incidence den-
sity of 57 per 1000 patient-days corresponding to 30.5% 
screened ICU admissions. In a multicenter study involving 75 
ICUs in all regions of Brazil 3128 patients were identified and 
521 (16.7%) were diagnosed as having infection, sepsis, or sep-
tic shock. The overall mortality in 28 days was 46.6%.5
Sepsis, similar to other systemic inflammatory response 
syndromes, is characterized by increased secretion of stress 
hormones (eg, catecholamines and cortisol), cytokine over-
production, complement activation, and mitochondrial dys-
function with decreased availability of adenosine triphosphate. 
Sepsis-related inflammation causes microcirculatory dys-
function, inadequate tissue oxygen supply, and subcellular and 
cellular dysfunction.6,7 Patients with organic dysfunction and 
hemodynamic instability present a high mortality rate from 
sepsis, and the application of adequate guideline-based ther-
apy is related to a significant decrease in mortality. Kumar 
et al found that a delay of more than 1 hour in initiating anti-
microbial use for unstable patients is related to higher mortal-
ity and so early diagnosis makes timely implementation of 
adequate therapy feasible.8 However, antimicrobial use in the 
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2 Biomarker Insights 
absence of infection has its adverse effects, including the 
development of multidrug resistant microorganisms9; there-
fore, it is important to differentiate sepsis from other causes 
of systemic inflammation.
Previous studies have also demonstrated an increase in cir-
culating phospholipase A2 type II (snp-PLA2) in patients 
with severe infection.10–16 Group IIA sPLA2 is an acute-phase 
protein that is expressed in various tissues and cells in response 
to a variety pro-inflammatory cytokines and it serves to amplify 
the inflammatory signal and mediates the various phenomena 
that are seen in the inflammatory process.14 Members of the 
sPLA2 family of enzymes generate important bioactive lipid 
mediators that include lysophosphospholipids and arachidonic 
acid and which can be converted to eicosanoids. Eicosanoids 
modulate cell growth and differentiation, immunity, inflamma-
tion, platelet aggregation, and many other functions. 
Eicosanoids produced from arachidonic acid by COX and 
LOX, respectively, are 2-series prostaglandins (PGs) and 
4-series leukotrienes that act as mediators of inflammatory 
processes.17
Elevated plasma-free fatty acid (FA) levels,18,19 changes of 
polyunsaturated FA (PUFA) metabolism,20,21 decreased 
lysophosphatidylcholine (lyso-PC) levels, and increased cera-
mide (Cer) species rates in plasma are commonly associated 
with sepsis.22–24
Biomarkers have been used in a variety of disease processes 
and can help aid in diagnosing bacterial infections or even in the 
severity of sepsis. None of the currently tested new markers has 
sufficient specificity or sensitivity to perform as diagnostic tools. 
Procalcitonin and C-reactive protein have been most widely 
used but even these have limited ability to predict outcomes and 
lack accuracy to distinguish sepsis from other inflammatory 
conditions.25 Profiles of lipids as accessed by lipidomics investi-
gations may provide a chance for early diagnosis of diseases and 
increase the possibility of successful treatment. Mass spectrom-
etry (MS) plays a prominent role in the lipid analysis. Although 
the initial cost of the equipment is high and laboratory expertise 
in the development, validation, and maintenance of MS-based 
assays may be limited, it still can be cost-effective for laborato-
ries to develop MS tests to avoid send-out costs on higher-vol-
ume tests.26 The advancement of this technology along with the 
development of new applications will accelerate the incorpora-
tion of MS into more areas of medicine.
Altered lipid profiles, along with the progress of diseases, 
together with genomics and proteomics, should provide new 
insights allowing a better understanding of the pathogenic 
mechanisms and to design new therapeutic strategies. Because 
sepsis and septic shock are accompanied by severe metabolic 
alterations, we hypothesize that a systematic characterization 
of lipids metabolites combined with multivariate data analysis 
should identify potential biomarkers. Herein we report on the 
gas chromatography (GC) and electrospray ionization quadru-
pole time-of-flight MS (ESI-MS q-ToF) monitoring of lipid 
profiles in plasma and erythrocyte membranes in the search of 
biomarkers that could diagnosis alterations in lipid dynamics in 
sepsis and septic shock.
Methods
Participants
This study has been approved by the Ethics Committee of the 
São Francisco University (CAEE 51356315.5.0000.5514). 
Written informed consent was obtained from the persons 
legally responsible for the patients according to the Declaration 
of Helsinki. This was a prospective study conducted in an adult 
medical ICU of the Hospital Universitário São Francisco na 
Providência de Deus (Bragança Paulista, SP, Brazil). A total In 
total, 65 patients admitted to the ICU during the study over a 
period of 16 months (2014 and 2015) were screened, 20 were 
included in the study (Figure 1) with sepsis (n = 9) and septic 
shock (n = 11). Exclusion criteria were age under 18 years, con-
genital lipid metabolism disorders, severe hemorrhagic distur-
bance, renal insufficiency, immunosuppressive therapy, and 
neoplasia. Blood samples were collected prior to initiation of 
enteral or parenteral therapy. The serum samples for healthy 
volunteers were collected at UNIFAG-USF (Unidade 
Integrada de Farmacologia e Gastroenterologia, Universidade 
São Francisco, Bragança Paulista, SP, Brazil) and revealed no 
clinically relevant abnormalities. Table 1 summarizes the major 
characteristics of all subjects.
Lipidomic analysis
Peripheral blood samples were drawn from patients within 
36 hours after their admission to the ICU. Plasma and leuko-
cytes were removed after centrifugation. Erythrocytes were 
washed and centrifuged twice. The samples were stored at 
−80°C until analysis. The blood samples of the control group 
(healthy volunteers) were subjected to the same procedure. 
Lipids from plasma and erythrocytes were extracted with chlo-
roform-methanol (2:1) and an aqueous solution of KCl.27 The 
lower lipid phase was collected and dried under nitrogen.
The separation of the phospholipids was performed using 
solid phase extraction with aminopropyl silica cartridges 
(Bond Elut NH2 cartridge; Agilent Technologies, Inc., 
Santa Clara, CA, USA).28 The lipid extracts were diluted in 
300 µL of methanol:chloroform (2:1) and 100 µL of this 
solution was rediluted in 400 µL of acetonitrile:chloroform 
(3:1), then 1 µL was injected into a MS using an LC (Agilent 
1290) without a column and with a flow of 0.5 mL min−1 of 
acetonitrile:H2O (1:1). The MS experiments were per-
formed on 6550 iFunnel q-ToF (Agilent Technologies) cou-
pled with a Dual Agilent Jet Stream ESI source 
(Dual-AJS-ESI). The positive ion mode was selected for the 
collection of the mass spectra using the following condi-
tions: gas temperature at 290°C, drying gas flow at 
11 L min−1, nebulizer at 45 psi, sheath gas temperature at 
350°C, sheath gas flow 12 L min−1 VCap 3000, nozzle volt-
age 320 V, fragmentor 100 V, and OCT 1 RFV pp 750 V. 
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Agilent Mass Hunter Qualitative Analysis software version 
B.07.00 was used to acquire and process the data. The 
ESI(+)-MS data were exported in Comma-Separated Values 
(CSV) files and statistical analyses were performed using 
MetaboAnalyst 2.0.
The FA composition of the phospholipids fraction of erythro-
cytes was determined by GC. The extracts were converted into FA 
methyl esters using BF3 methanol29 and a GC (Tech, Inc., Apple 
Valley, MN, USA) with a flame ionization detector equipped with 
a polar CP-Sil 88 column was used.30 Fatty acid identification was 
Figure 1. Patient selection flowchart.
Table 1. Demographic data and major clinical characteristics of septic patients and healthy volunteers.
SEPTIC PATIENTS HEALTHy vOLUNTEERS
N 20 20
Sex (M/F) 11:9 10:10
Age, y 55.7 ± 18.1 58.1 ± 11.2
BMI, kg/m2 23.4 ± 4.8 21.8 ± 3.7
Albumin, g/L 2.8 ± 0.3 4.3 ± 0.5
C-reactive protein, mg/dL* 236.8 ± 82.4* 0.38 ± 0.24
Sepsis, No. (%) 9 (45) —
Septic shock, No. (%) 11 (55) —
APACHE II 14.8 ± 6.4 —
SAPS III 48.9 ± 31.7  
SOFA score 6.3 ± 4.1 —
Primary site of infection —
Lungs (pneumonia) 15 (75)  
Urinary tract 3 (15)  
Abdomen 2 (10)  
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; SAPS III, Simplified Acute Physiology Score III; SOFA, Sequential 
Organ Failure Assessment.
Data presented as mean ± SD.
*P < .001 compared with healthy volunteers.
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made by comparing retention times with authentic standards 
(Sigma-Aldrich, St. Louis, MO, USA) injected under the same 
conditions. Fatty acid composition was determined by comparing 
the retention times with authentic standards (Sigma-Aldrich) and 
calculating the relative percentages.
Statistical analysis
For the statistical analysis, each molecular feature (ion) was nor-
malized by sum, and unsupervised segregation was evaluated 
using statistical Web platform MetaboAnalyst. Principal compo-
nent analysis (PCA) was performed using Pareto and the results 
were used to show the lipids that most strongly influence the dis-
crimination between groups. To enhance data discrimination, the 
data were also analyzed using the (orthogonal) partial least 
squares discriminant analysis ((O)PLS-DA) method. Biomarkers 
were selected according to their variable importance in projection 
(VIP) values. In addition, an independent t test (P ≤ .05) was used 
to evaluate whether different biomarker candidates were statisti-
cally significant between groups. The differences of FA composi-
tion between groups were analyzed by 1-way analysis of variance, 
followed by the Tukey test and P < .05 was considered to be statis-
tically significant.
Results
To access data quality of lipid matrix data, we first performed 
an unsupervised multivariate method (PCA) because it may 
show sample outliers and/or reveal hidden biases (Figure 2). 
Our previous results showed 3 possible subgroups in septic 
patients, which are further correlated with primary site of 
Figure 2. Top left: PCA scores plot of PC1 (first principal component) vs PC2 (second principal component) showing the separation between healthy 
volunteers (red) and septic patients (green). Top right: Loadings plot for PC1 and PC2 showing the metabolite ions (m/z) that were major contributors to 
the separation of groups observed in PCA scores plot. Bottom left: PLS-DA discrimination of MS spectra from healthy volunteers (red) and septic patients 
(green). Bottom right: Loadings plot for PC1 and PC2 showing the metabolite ions (m/z) that were major contributors to the separation of groups observed 
in PLS-DA scores plot. Analysis without previous variable selection. PCA indicates principal component analysis; PLS-DA, partial least squares 
discriminant analysis.
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infection. Because of their difference, we selected only septic 
patient from pneumonia infection as there were few number of 
other septic patients. For the statistical data analysis, the data 
of septic patient from pneumonia infection were used in the 
multivariate variable selection (MVS) to improve statistical 
results. After variable selection, the explain variance increased 
to 65% in the first 2 PCs showing the improvement of data 
analysis (Figure 3). To access the major changes in lipid analy-
sis between septic patients and healthy volunteers, we therefore 
also performed supervised statistical methods: a PLS-DA 
(Figure 4), an (O)PLS-DA (Figure 5), and cross-validation and 
permutation tests from PLS-DA (Figure 6). Both protocols 
show great robustness as indicated by their low P values in per-
mutation tests (P < 5e−4).
Possible sepsis biomarkers were revealed via VIP variables 
with high statistical significance. Figure 4 shows top 15 signifi-
cant features of the metabolite markers based the VIP projec-
tion. Potential metabolites of significant contribution are listed 
in Table 2. Results from PLS-DA and (O)PLS-DA were also 
quite similar showing minimal or no response (Y) uncorrelated 
variation in the data after variable selection. The major changes 
in the lipid profiles between septic patients and healthy volun-
teers were seen for the phosphosphingolipids and glycerophos-
phocholine classes (Figure 7). The abundances of the di-, 
monounsaturated, and/or saturated phosphosphingolipid ions 
of m/z 703, 717, 757, 785, 787, 789, 799, 801, 813, and 815 in 
septic patients were significantly decreased (Table 2). The 
abundances of the lyso-PC ions of m/z 482, 496, 518, 520, 522, 
524, 542, 544, and 546 also decreased, whereas the saturated 
and unsaturated phosphatidylcholine (PC) ions of m/z 744, 
758, 760, 780, and 782 also increased in septic patients. In 
addition, a cardiolipin ion of m/z 1518 and a phosphatidylser-
ine (PS) ion of m/z 846 were found as upregulated lipids by the 
statistical analysis (Table 2). Figure 8 shows 2 representative 
examples of ESI(+)-MS (q-ToF) of plasma lipid extract from 
healthy and septic patients.
Table 3 presents the major FA detected by GC for the 
erythrocyte phospholipids of septic patients and healthy volun-
teers. Data are given as percentage of the phospholipid fatty 
acyl species. The FA pattern in septic patients showed a marked 
increase in the sum of monounsaturated fatty acid (MUFA), 
that is, mainly oleic acid (18:1 n-9) increases accompanied by a 
decrease in total n-3 PUFA, whereas saturated and n-6 PUFA 
remains substantially unaltered. These trends lead to a 16% 
increase in the MUFA/n-6 ratio and to a 24% decrease in the 
unsaturation index. Figure 9 shows the percentage of different 
subclasses of FA in the erythrocyte phospholipid fraction.
Discussion
Glycerophosphocholine role in sepsis
Our results show that the major changes in glycerophospho-
choline species between septic and healthy patients were in 
monoacyl (lyso-PC) and diacylglycerophosphocholine (PC) as 
indicated by the PLS-DA analysis of the ESI-MS lipid profile 
data (Figure 4). We observed therefore an upregulation in PC 
and a downregulation in lyso-PC species in lipid extracts of 
both plasma and erythrocytes. The lyso-PC results from the 
action of phospholipase A2, which liberates arachidonic 
acid from PC. The action of lyso-PC on immunoregulatory 
cells is very diverse and they participate in many induced 
inflammation signaling pathway.31 Erythrocyte membrane 
Figure 3. Left: PCA scores plot of PC1 (first principal component) vs PC2 (second principal component) showing the separation between healthy 
volunteers (red) and septic patients (green). Right: Loadings plot for PC1 and PC2 showing the metabolite ions (m/z) that were major contributors to the 
separation of groups observed in PCA scores plot. Analysis after previous variable selection with the data of septic patient from pneumonia infection was 
used in the multivariate variable selection (MvS) to improve statistical results. PCA indicates principal component analysis.
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phospholipids reflect systemic changes caused by inflammatory 
response and oxidative stress in septic patients. Their role in 
inflammation process is known to be very complex and is not 
completely understood, whereas their plasma composition can 
be directly influenced by diet.32 Generally, lyso-PC is upregu-
lated at sites of inflammation, but in sepsis, an acute systemic 
inflammatory condition, decreased levels of lyso-PC/PC ratios 
were observed (Figure 7). Such reduced ratio has been 
correlated with sepsis mortality.22 This correlation was also 
corroborated by Yan et al33 who found that therapeutic admin-
istration of lyso-PC after induction of sepsis effectively inhib-
ited lethality in mouse models. In addition, Dinkla et  al16 
showed that lyso-PC formation increases in in vitro studies 
when erythrocytes of healthy patients were treated with plasma 
of septic patients. These trends may be contradictory due to 
pro-inflammatory effects of lyso-PC, but their decrease could 
Figure 4. Left: Scores from PLS-DA discrimination of ESI-MS data from healthy volunteers (red) and septic patients (green). Right: Important metabolite 
ions selected on the basis of vIP score. The colored boxes on the right indicate relative bin integrals from healthy volunteers and septic patients. vIP 
score is a weighted sum of squares of PLS-DA loadings taking into account the amount of explained Y-variation in each dimension. See Figures 2 and 6 
for the loading plots, permutation, and cross-validation tests. ESI-MS, electrospray ionization mass spectrometry; PLS-DA, partial least squares 
discriminant analysis; vIP, variable importance in projection.
Figure 5. Left: (O)PLS-DA scores plot form comparison of the metabolite profiles of healthy volunteers (red) and septic patients (green). 36.5% and 11.9% 
are the scores of the T score and orthogonal T score, respectively. Right: Loadings plot for feature importance showing the metabolite ions (m/z) that were 
contributors to separation groups observed in (O)PLS-DA score plot. Analysis after previous variable selection. (O)PLS-DA indicates (orthogonal) partial 
least squares discriminant analysis.
Mecatti et al 7
be a later response to inflammation due to anti-inflammatory 
lyso-PA production.
A metabolomic study performed by Kamisoglu et al24 has 
found that 5 lyso-PC species decreased significantly in the 
experimental and clinical studies of sepsis. The lyso-PC con-
centration on day 7 was significantly lower in nonsurvivors and 
lyso-PC concentrations increased over time in patients treated 
with appropriate antibiotics but not in those treated with inap-
propriate antibiotics.34 The authors found that serial measure-
ments of lyso-PC helped in the prediction of 28-day mortality 
in ICU patients with severe sepsis or septic shock.
The lysophosphatidic acid (lyso-PA) production occurs by 
action of autotaxin, a plasma lysophospholipase D35 which acts 
in lyso-PC hydrolysis and promotes lyso-PA’s anti-inflamma-
tory action on macrophages.36 Via ESI-MS, we failed to detect 
any sign of lyso-PA, maybe because they are locally formed and 
rapidly degraded in vivo.37–39 Finally, we observed a PS increase 
in septic patients, and this increase could be related to lyso-PA 
production because they also induce PS exposure of erythro-
cytes during endotoxemia.16
We also noted that Drobnik et al22 have shown a decreased 
lyso-PC/PC and increased Cer/SM ratios in septic patients as 
compared with healthy control subjects. These findings cor-
roborate the strong predictive factors for sepsis-related mortal-
ity for such ratios. Highly increased PCs seem to be sepsis 
specific because they are not detectable in systemic inflamma-
tory response syndrome samples without infection compared 
with ICU control subjects.40
Phosphosphingolipids
Inflammation triggers the acid sphingomyelinase (SMase) 
which catalyzes the hydrolysis of SM, a major component of cell 
membranes, into phosphocholine and Cer.41 These changes alter 
membrane curvature and decrease plasma membrane integrity 
enhancing PS exposure and erythrocyte clearance, contributing 
to anemia. Erythrocytes do not possess SMase activity of their 
own, but they can be exposed to secreted SMases,23,42 herein we 
observed an SM concentration decrease in septic patients (Table 
2, Figure 7), but the corresponding formation of Cer was not 
observed in the lipid extracts of both plasma and erythrocytes. 
These findings agreed with those from Dinkla et  al16 who 
observed that erythrocytes are very sensitive to Cer-induced 
changes in membrane organization suggesting that, in vivo, these 
changes quickly triggered erythrocyte clearance.43
FA profile
The FA profile of plasma phospholipids seemed very interest-
ing because these molecules carry the most important part of 
PUFA which serve as precursors for signaling molecules 
(eicosanoids and docosanoids).44 The phospholipids FA profile 
is also less affected by fat intake than other plasma lipids, ie, 
triacylglycerols or nonesterified FAs. The changes of FA profile 
from erythrocytes phospholipids in septic patients were associ-
ated mainly by an increase in oleic acid levels (C18:1 n-9) 
accompanied by a proportional decrease in n-3 PUFA and n-6 
PUFA levels (Table 3). Oleic acid is produced by stearoyl-CoA 
desaturase (SCD1), which is an enzyme localized in the endo-
plasmic reticulum that converts palmitoyl-CoA (C16:0) and 
stearoyl-CoA (C18:0) to palmitoleoyl-CoA (16:1) and oleoyl-
CoA (18:1), respectively, with stearoyl-CoA being the main 
substrate.45 These MUFAs are the key components of triglyc-
erides and membrane phospholipids. The higher percentage of 
oleic acid could reflect an adipose-stimulated lipolysis which 
has been observed in septic shock patients. Such high percent-
ages have been associated with a rising plasma nonesterified 
FA concentrations, hypoalbuminemia, and reduction in energy 
supply to the organs.18,19,46 The elevation of plasma nonesteri-
fied FA levels has been reported to produce important myocar-
dial damage, arrhythmias, and reduction in heart rate variability 
in septic patients.18 The decrease in energy supply to the organs 
contributes therefore to multiple organ failure and death.47 
Although the oleic acid affects different biological processes, 
Figure 6. Left: Cross-validation showing the 3 performance measures (prediction accuracy, R2, and Q2) using different numbers of components. * 
indicates the best values of the currently selected measures Q2 (0.86). Right: the result of permutation test statistics summarized by a histogram (P < 5e−4).
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10 Biomarker Insights 
Figure 7. Typical ESI(+)-MS of erythrocyte membrane showing lipid profiles for (A) healthy and (B) septic patients. (C) Lyso-PC/PC and SM/PC ratios for 
healthy and septic patients. Lyso-PC/PC ratio for healthy and septic patients was determined dividing the combined pool of lyso-PC (16:0, 18:3, 18:2, 18:1, 
18:0, 20:5, 20:4, and 20:3) by the combined pool of PC (16:X/18:Y − X + Y = 1-2, 16X/20Y X + Y = 1-5) from healthy and septic patients. The SM/PC ratio for 
healthy and septic patients was determined dividing the combine pool of SM(d18:1/16:0, d18:1/24:1, d18:1/24:0, d16:1/24:1, 16:1/24:0) by combined pool of 
PC from healthy and septic patients. For more detailed lipid class composition, see Table 2. ESI(+)-MS indicates electrospray ionization mass 
spectrometry; lyso-PC, lysophosphatidylcholine; SM, sphingomyelin.
Figure 8. Two representatives examples of ESI(+)-MS of plasma lipid extract from (A) healthy and (B) septic patients. ESI(+)-MS indicates electrospray 
ionization mass spectrometry; PC, phosphatidylcholine.
such as decreases plasma-free FA concentration and increases 
CPT1A and UCP2 and AMPK levels, decreasing levels of 
reactive oxygen species in septic mice, its detailed mechanism 
of action is still not completely understood.48
Our results show decline in PUFAs (more specifically 
>20 carbons) which could result either from their 
degradation by peroxidation from reactive oxygen species or 
to a higher synthesis of inflammatory lipid mediators 
because these PUFAs are the precursors of eicosanoids 
(prostaglandins, prostacyclins, and thromboxanes) and doc-
osanoids (protectins and resolvins) which are involved in 
inflammation, vasomotricity, and capillary permeability.49 
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Our results are consistent with those described by Rival 
et  al21 which observed high percentage of saturated fatty 
acids and MUFAs with low concentrations of plasma phos-
pholipid n-6 and n-3 PUFAs in patients with septic shock. 
Barros et al50 observed altered FA profiles in plasma PC in 
critically ill patients, mostly diagnosed with sepsis and sep-
tic shock, compared with healthy elderly subjects. Surviving 
ICU patients displayed higher levels of docosahexaenoic 
acid and total n-3 PUFA and a lower n-6/n-3 PUFA ratio in 
plasma PC than nonsurvivors.
Conclusions
A total of 29 potential biomarkers for sepsis and septic shock 
have been identified via ESI-MS (q-ToF) lipid profile screen-
ing. Most contrasting lipids were from the phosphosphin-
golipids and glycerophosphocholine classes which were 
observed in all samples with significant variations in abun-
dances between septic patients and healthy controls. Septic 
patients also displayed erythrocyte membranes characterized 
by higher levels of oleic acid and lower levels of n-6 PUFA, 
hence with reduced unsaturation indexes. Combined with the 
above analysis, we believe that lyso-PC (16:0) and SM may 
both be involved in the pathogenesis of sepsis and hope that 
they can be developed as sensitive and specific diagnostic bio-
markers candidates of sepsis, which require confirmation in 
further functional studies and large-sample validation. We 
have confirmed the metabolic alterations of some functional 
lipids that may support the understanding of the pathogenesis 
of sepsis. A limiting factor in this study is the small number of 
research subjects, and more studies are needed for more robust 
conclusions. In this study, other groups of patients, such as 
those with inflammatory process without organ dysfunction, 
Table 3. FA composition of the erythrocyte phospholipids of both septic patients and healthy volunteers (% relative of total FA).
SEPTIC PATIENTS HEALTHy vOLUNTEERS
Palmitic acid (C16:0) 31.25 ± 1.15 29.96 ± 1.23
Stearic acid (C18:0) 17.27 ± 1.33 16.68 ± 1.09
Total SFAs 48.52 ± 1.64 46.64 ± 1.45
Palmitoleic acid (C16:1 n-7) 2.03 ± 0.38 2.51 ± 0.84
Oleic acid (C18:1 n-9) 18.58 ± 0.84* 15.41 ± 1.05
Total MUFAs 20.61 ± 0.86* 17.92 ± 1.14
Linoleic acid (C18:2 n-6) 13.35 ± 2.59 15.14 ± 1.44
Arachidonic acid (C20:4 n-6) 13.20 ± 1.98 13.52 ± 1.87
Total n-6 PUFAs 26.54 ± 2.10 28.66 ± 1.63
Linolenic acid (C18:3 n-3) 0.57 ± 0.07 0.44 ± 0.13
Eicosapentaenoic acid (C20:5 n-3) 0.72 ± 0.23 1.02 ± 0.44
Docosapentaenoic acid (C22:5 n-3) 1.67 ± 0.28* 2.57 ± 0.38
Docosahexaenoic acid (C22:6 n-3) 1.42 ± 0.16* 2.83 ± 0.21
Total n-3 PUFAs 4.38 ± 0.72* 6.87 ± 0.74
n-6 PUFAs/n-3 PUFAs 6.05 ± 1.83 4.19 ± 2.05
MUFA/n-6 PUFAs 0.77 ± 0.23 0.62 ± 0.12
Unsaturation index 122 154
Abbreviations: MUFA, monounsaturated fatty acids; n-3 PUFA, n-3 polyunsaturated fatty acids; n-6 PUFA, n-6 polyunsaturated fatty acids; SFA, saturated fatty acid.
*P < .05 compared with healthy volunteers (Tukey test).
Figure 9. Percentages of different subclasses of fatty acids in the 
erythrocyte phospholipid fraction. MUFA indicates monounsaturated fatty 
acids; n-3 PUFA, n-3 polyunsaturated fatty acids; n-6 PUFA, n-6 
polyunsaturated fatty acids; SFA, saturated fatty acid. *P < .05 compared 
with healthy volunteers (Tukey test).
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were not evaluated. Possibly, the combinations of lipidome 
profile with others pro- and anti-inflammatory biomarkers in 
a multimarker panel may help identify patients who are devel-
oping sepsis before organ dysfunction has advanced too far. 
Such knowledge is crucial due to the high severity and mortal-
ity of this disease and may help to in the design of clinical 
diagnosis, sepsis monitoring, and therapy.
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